MEI Pharma, Inc. is a late-stage pharmaceutical company focused on developing new therapies for cancer. MEI Pharma’s portfolio of clinical stage drug candidates includes the lead candidate zandelisib (ME-401), an oral PI3Kdi differentiated by its unique dosing schedule currently under evaluation for R/R FL and MZL in Phase 2 (NCT03768505) and Phase 3 (NCT04745832) clinical trials intended to support market authorization applications, as well as voruciclib, an oral CDK9 inhibitor currently evaluated in a Phase 1 (NCT03547115) clinical trial for R/R B-cell malignancies and AML.